Dr. Ryan Rader, MD
Hematology & Oncology (Hematology & Oncology Physician)
- Medicare participating
At a glance
- Medical school
- University of Missouri, Columbia School of Medicine (2017)
- Years since graduation
- 9
- In the NPI registry since
- 2017
- Medicare patients seen, 2024
- 235
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2017Medical school: University of Missouri, Columbia School of Medicine
- 2017Registered with an NPI (national billing number; not a license date)
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Hematology & Oncology Physician primary
MO license 2023010486 · KS license 04-47947
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- University of Kansas Hospital Kansas City, KS
- Saint Luke's East Hospital Lees Summit, MO
- Lee's Summit Medical Center Lees Summit, MO
- Golden Valley Memorial Hospital Clinton, MO
- St Mary's Medical Center Blue Springs, MO
Medical groups
- University of Kansas Hospital Authority (250 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 235
- Services billed
- 732
- Patients’ average age
- 73
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 30-39 minutes | 23 | 23 |
| Established patient office or other outpatient visit, 40-54 minutes | 23 | 18 |
| Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | 17 | 16 |
| New patient office or other outpatient visit, 30-44 minutes | 12 | 12 |
| Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | 11 | 11 |
| New patient office or other outpatient visit, 45-59 minutes | 11 | 11 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Anastrozole Other prescribers in Lees Summit, MO | 265 |
| Letrozole Other prescribers in Lees Summit, MO | 106 |
| Alendronate Sodium Other prescribers in Lees Summit, MO | 81 |
| Tamoxifen Citrate Other prescribers in Lees Summit, MO | 42 |
| Gabapentin Other prescribers in Lees Summit, MO | 38 |
| Ondansetron Hcl Other prescribers in Lees Summit, MO | 33 |
| Exemestane | 32 |
| Oxycodone Hcl Other prescribers in Lees Summit, MO | 30 |
| Verzenio (abemaciclib) | 29 |
| Dexamethasone Other prescribers in Lees Summit, MO | 23 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 7 companies reported 9 payments worth $2,110 in total to this clinician.
| Gilead Sciences, Inc. | $1,160 |
|---|---|
| AstraZeneca Pharmaceuticals LP | $709 |
| Myriad Genetic Laboratories, Inc. | $96.32 |
| Stemline Therapeutics Inc. | $85.10 |
| GlaxoSmithKline, LLC. | $24.94 |
| Regeneron Healthcare Solutions, Inc. | $23.36 |
| Pfizer Inc. | $11.88 |
| Consulting Fee | $1,845 |
|---|---|
| Food and Beverage | $254 |
| Education | $11.88 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Gilead Sciences, Inc. Oct 9, 2025 | Consulting Fee Trodelvy · ONC Company’s description;4238255;VEM US;19726373 | $1,160 |
| AstraZeneca Pharmaceuticals LP Feb 13, 2025 | Consulting Fee | $685 |
| Pfizer Inc. Jul 21, 2025 | Education IBRANCE · ONCOLOGY · in-kind | $11.88 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 1 industry-funded study in 2025, from 1 company. The companies reported $10,000 in research payments for these studies, mostly to the institutions running them.
- The COMPASSHER2 trials comprehensive use of pathologic response assessment to optimize therapy in HER2POSITIVE breast cancer COMPASSHER2 residual disease rd a doubleblinded phase iii randomized trial of TDM1 compared …
Pfizer Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.